This triple fixed-dose combination brings together Glimepiride, Voglibose, and sustained-release Metformin Hydrochloride, addressing both fasting and postprandial glucose control in type 2 diabetes mellitus.

Each unit of this triple combination antidiabetic tablet contains Glimepiride IP 2 mg + Voglibose IP 0.2 mg + Metformin Hydrochloride IP 500 mg (sustained release), formulated in tablets form and manufactured in compliance with Indian Pharmacopoeia (IP) standards. This ensures uniform potency and quality across every production batch, a key requirement for pharmaceutical importers and distributors evaluating comprehensive type 2 diabetes therapy medication for their regional markets.

Intended for patients with type 2 diabetes mellitus requiring a triple-agent oral therapy regimen, as prescribed by a physician. Suitable for hospital and pharmacy channel distribution.

Supplied in 10x10 blister strips, designed for reliable performance through international shipping and storage. The 10x10 Tablets configuration is widely used in international pharmaceutical trade, supporting efficient inventory management for wholesalers and institutional buyers sourcing three-drug fixed-dose formulation in bulk quantities.

CD&M Remedies is an established manufacturer of IP-compliant pharmaceutical formulations, supplying triple combination antidiabetic tablet to B2B buyers and importers worldwide. Buyers benefit from consistent formulation quality, reliable supply capability, and export-oriented packing suited to cross-border pharmaceutical trade.

Q: What is the composition of Glimepiride Voglibose And Metformin Hcl Sustained Release Tablets Cdpride-Mv2?
A: It contains Glimepiride IP 2 mg + Voglibose IP 0.2 mg + Metformin Hydrochloride IP 500 mg (sustained release), manufactured to Indian Pharmacopoeia (IP) standards in tablets form.

Q: What pack sizes are available for Glimepiride Voglibose And Metformin Hcl Sustained Release Tablets Cdpride-Mv2?
A: This product is supplied in 10x10 Tablets export packing, suitable for wholesale and institutional bulk orders.

Q: Who manufactures Glimepiride Voglibose And Metformin Hcl Sustained Release Tablets Cdpride-Mv2?
A: Glimepiride Voglibose And Metformin Hcl Sustained Release Tablets Cdpride-Mv2 is manufactured and supplied by CD&M Remedies, under product code 1008.

Q: Which product category does Glimepiride Voglibose And Metformin Hcl Sustained Release Tablets Cdpride-Mv2 belong to?
A: It falls under the Anti-Diabetic Combination Medication category, intended for B2B pharmaceutical buyers and importers.